MiMedx Group (MDXG) vs Sagimet Biosciences Series A (SGMT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Sagimet Biosciences Series A (SGMT) has outperformed MiMedx Group (MDXG) over the past year, gaining 3.6% versus a loss of 32.5%. MiMedx Group is the larger company by market cap ($681.5 million vs $633.2 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MDXG | SGMT |
|---|---|---|
| Share price | $4.67 | $8.93 |
| Market cap | $681.51M | $633.21M |
| 1-day change | +1.08% | +0.11% |
| YTD return | -31.02% | +50.84% |
| 1-year return | -32.51% | +3.60% |
| 5-year return | -30.92% | — |
| P/E ratio (TTM) | 116.75 | — |
| Forward P/E | 23.35 | — |
| EPS (TTM) | $0.04 | $-1.27 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $7.97 | $11.45 |
| 52-week low | $3.03 | $4.50 |
| Distance from 52-week high | -41.41% | -22.00% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +58.46% | +212.54% |
| Average volume | 1.22M | 1.24M |
| Shares outstanding | 145.93M | 70.34M |
| Employees | 808 | 16 |
| Sector | Health Care | Health Care |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- SGMT has outperformed MDXG by 36.1 percentage points over the past year.
About MiMedx Group
MDXG stock →MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare.
Health Care · Medical/Dental Instruments · 808 employees
About Sagimet Biosciences Series A
SGMT stock →Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic and fibrotic pathways in the United States. The company's lead drug candidate is Denifanstat, an oral, once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction-associated steatohepatitis, acne, and select forms of cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 16 employees
MDXG vs SGMT FAQ
Which is bigger, MiMedx Group or Sagimet Biosciences Series A?
MiMedx Group (MDXG) is larger, with a market capitalization of $681.51M compared with $633.21M for Sagimet Biosciences Series A (SGMT).
Which stock has performed better over the past year, MDXG or SGMT?
SGMT returned +3.60% over the past 12 months, compared with -32.51% for MDXG (price return, excluding dividends). Past performance does not predict future results.
Are MiMedx Group and Sagimet Biosciences Series A in the same industry?
Both are in the Health Care sector, but in different industries: Medical/Dental Instruments for MiMedx Group and Biotechnology: Pharmaceutical Preparations for Sagimet Biosciences Series A.